Volume 29, Issue 2 (Iran South Med J 2026)
Iran South Med J 2026, 29(2): 79-88 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bagheri N, Safavi M, Ghasemi Dehnoo M, Rafieian Kopaei M, Azadegan Dehkordi F. Effects of Quinic Acid and Syringic Acid on Tissue IL-36α Expression in an Acetic Acid Induced Ulcerative Colitis Model. Iran South Med J 2026; 29 (2) :79-88
URL: http://ismj.bpums.ac.ir/article-1-2545-en.html
URL: http://ismj.bpums.ac.ir/article-1-2545-en.html
Nader Bagheri1 
, Maryam Safavi2 , Maryam Ghasemi Dehnoo3 , Mahmoud Rafieian Kopaei4 , Fatemeh Azadegan Dehkordi *5
, Maryam Safavi2 , Maryam Ghasemi Dehnoo3 , Mahmoud Rafieian Kopaei4 , Fatemeh Azadegan Dehkordi *5
1- Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
2- Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
3- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
4- Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
5- Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran ,azadegan.f@skums.ac.ir
2- Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
3- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
4- Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
5- Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran ,
Abstract: (205 Views)
Background: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by excessive production of pro-inflammatory cytokines and progressive mucosal damage. IL-36α, a member of the IL-1 cytokine family, plays an important role in amplifying inflammatory responses. This study aimed to investigate the effects of quinic acid (QA) and syringic acid (SA) on IL-36α levels in an experimental model of UC.
Materials and Methods: UC was induced in male Wistar rats by intrarectal administration of 4% acetic acid. The animals were divided into control, colitis, dexamethasone-treated, QA-treated (10, 30, 60, and 100 mg/kg), and SA-treated (10, 25, and 50 mg/kg) groups. After 7 days of treatment, IL-36α levels in colon tissue were measured using ELISA.
Results: Induction of UC significantly increased IL-36α levels from 106.9 ± 8.69 pg/mL in the control group to 420.6 ± 59.50 pg/mL in the colitis group (P < 0.0001). Dexamethasone significantly reduced IL-36α levels to 108.7 ± 12.18 pg/mL (P < 0.0001). QA treatment resulted in a dose-dependent reduction in IL-36α levels, with values of 390.2 ± 47.72, 332.3 ± 72.49, 232.5 ± 60.57, and 170.7 ± 24.01 pg/mL at 10, 30, 60, and 100 mg/kg, respectively. Similarly, SA significantly decreased IL-36α levels to 355.4 ± 52.43, 306.8 ± 77.06, and 183.0 ± 33.70 pg/mL at 10, 25, and 50 mg/kg, respectively (P = 0.04, P=0.0001, and P<0.0001).
Conclusion: Both QA and SA exert significant anti-inflammatory effects in experimental UC and may modulate inflammatory responses through reducing IL-36α levels.
Materials and Methods: UC was induced in male Wistar rats by intrarectal administration of 4% acetic acid. The animals were divided into control, colitis, dexamethasone-treated, QA-treated (10, 30, 60, and 100 mg/kg), and SA-treated (10, 25, and 50 mg/kg) groups. After 7 days of treatment, IL-36α levels in colon tissue were measured using ELISA.
Results: Induction of UC significantly increased IL-36α levels from 106.9 ± 8.69 pg/mL in the control group to 420.6 ± 59.50 pg/mL in the colitis group (P < 0.0001). Dexamethasone significantly reduced IL-36α levels to 108.7 ± 12.18 pg/mL (P < 0.0001). QA treatment resulted in a dose-dependent reduction in IL-36α levels, with values of 390.2 ± 47.72, 332.3 ± 72.49, 232.5 ± 60.57, and 170.7 ± 24.01 pg/mL at 10, 30, 60, and 100 mg/kg, respectively. Similarly, SA significantly decreased IL-36α levels to 355.4 ± 52.43, 306.8 ± 77.06, and 183.0 ± 33.70 pg/mL at 10, 25, and 50 mg/kg, respectively (P = 0.04, P=0.0001, and P<0.0001).
Conclusion: Both QA and SA exert significant anti-inflammatory effects in experimental UC and may modulate inflammatory responses through reducing IL-36α levels.
Original: Original |
Subject:
Microbiology and Immunology
Received: 2026/05/19 | Accepted: 2026/07/14 | Published: 2026/07/29
Received: 2026/05/19 | Accepted: 2026/07/14 | Published: 2026/07/29
References
1. Park S, Abdi T, Gentry M, et al. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol 2016; 111(12): 1692-1701. [DOI]
2. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991; 325(13): 928-937. [DOI]
3. Logan I, Bowlus CL. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010; 9(5): A372-378. [DOI]
4. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180(6): 2359-2364. [DOI]
5. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122(1): 44-54. [DOI]
6. Vogel IC, Verganista MJ, Candeias NR. Quinic Acid and Synthetic Derivatives in Medicinal Chemistry. ChemMedChem 2026; 21(5): e202500976. [DOI]
7. Zhao Y, Wu J, Liu X, et al. Decoding nature: multitarget anti-inflammatory mechanisms of natural products in the TLR4/NF-κB pathway. Front Pharmacol 2024; 15: 1467193. [DOI]
8. Zhao Z, Yang Q, Sun Y, et al. Unveiling the antioxidant and anti-inflammatory potential of syringic acid: mechanistic insights and pathway interactions. Front Pharmacol 2025; 16: 1615294. [DOI]
9. Ghasemi-Dehnoo M, Amini-Khoei H, Lorigooini Z, et al. Ferulic acid ameliorates ulcerative colitis in a rat model via the inhibition of two LPS-TLR4-NF-κB and NF-κB-INOS-NO signaling pathways and thus alleviating the inflammatory, oxidative and apoptotic conditions in the colon tissue. Inflammopharmacology 2023; 31(5): 2587-2597. [DOI]
10. Ekhtiar M, Ghasemi-Dehnoo M, Mirzaei Y, et al. The coumaric acid and syringic acid ameliorate acetic acid-induced ulcerative colitis in rats via modulator of Nrf2/HO-1 and proinflammatory cytokines. Int Immunopharmacol 2023; 120: 110309. [DOI]
11. Ghasemi-Dehnoo M, Lorigooini Z, Amini-Khoei H, et al. Quinic acid ameliorates ulcerative colitis in rats, through the inhibition of two TLR4-NF-κB and NF-κB-INOS-NO signaling pathways. Immun Inflamm Dis 2023; 11(8): e926. [PubMed]
12. Russell SE, Horan RM, Stefanska AM, et al. IL-36α expression is elevated in ulcerative colitis and pro-motes colonic inflammation. Mucosal Immunol 2016; 9(5): 1193-1204. [DOI]
13. Nishida A, Hidaka K, Kanda T, et al. Increased Expression of Interleukin-36, a Member of the Inter-leukin-1 Cytokine Family, in Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22(2): 303-314. [DOI]
14. Fonseca-Camarillo G, Furuzawa-Carballeda J, Itur-riaga-Goyon E, et al. Differential Expression of IL-36 Family Members and IL-38 by Immune and Nonimmune Cells in Patients with Active Inflamma-tory Bowel Disease. Biomed Res Int 2018; 2018: 5140691. [DOI]
15. Nakase H, Sato N, Mizuno N, et al. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2022; 21(3): 103017. [DOI]
16. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20(1): 91-99. [DOI]
17. Ekhtiar M, Ghasemi-Dehnoo M, Azadegan-Dehkordi F, et al. Evaluation of Anti-Inflammatory and Antioxidant Effects of Ferulic Acid and Quinic Acid on Acetic Acid-Induced Ulcerative Colitis in Rats. J Biochem Mol Toxicol 2025; 39(2): e70169. [DOI]
18. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14(5): 329-342. [DOI]
19. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006; 148(3): 245-254. [DOI]
20. Iliev ID, Ananthakrishnan AN, Guo CJ. Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nat Rev Microbiol 2025; 23(8): 509-524. [DOI]
21. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 2017; 14(10): 573-584. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
